OOIR: Observatory of International Research

Papers

(The H4-Index of Translational Neurodegeneration is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes	1196
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential	178
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration	169
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond	111
Advances in the development of new biomarkers for Alzheimer’s disease	101
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases	84
COVID-19 and Alzheimer’s disease: how one crisis worsens the other	78
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	59
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	57
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy	56
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study	55
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut	54
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review	53
Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications	52
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease	48
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease	47
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	43
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	43
Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease	40
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation	38
Circadian disruption and sleep disorders in neurodegeneration	37
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases	37
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms	35
Mitochondrial links between brain aging and Alzheimer’s disease	34
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	34

A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?	33
Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases	33
Prodromal Parkinson's disease: hype or hope for disease-modification trials?	32
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases	32
The effects of transcranial direct current stimulation on gait in patients with Parkinson’s disease: a systematic review	31
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy	30